Joint Position Statement of the Polish Cardiologic Society, the Polish Gynaecological Society and the Polish Menopause and Andropause Society on the effect of postmenopausal hormone replacement therapy on the cardiovascular system

References

• The consensus of Polish Forum for Prevention Guidelines on Cardiovascular Diseases in Women. Forum Profilaktyki 2006; 3
   Google Scholar
• Salpeter S R, Walsh J M, Ormiston T M, Greyber E, Buckley N S, Salpeter E E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8: 538–554
   PubMed Web of Science ®Google Scholar
• Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment on the epidemiologic evidence. Prev Med 1991; 20: 47–64
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin S, Petitti D B, Fox C S, Black D, Ettinger B, Ernster V L, Cummings S R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 321–330
   Google Scholar
• Grodstein F, Stampfer M, Manson J, Colditz G A, Willett W C, Rosner B, Speizer F E, Hennekens C H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–461
   PubMed Web of Science ®Google Scholar
• Ottesen B, Sorensen M B. Women at cardiac risk: is HRT the route to maintaining cardiovascular health?. Int J Gynaecol Obstet 1997; 59(Suppl 1)S19–S27
   Google Scholar
• Sullivan J M, Vander Zwaag R, Lemp G F, Hughes J P, Maddock V, Kroetz F W, Ramanathan K B, Mirvis D M. Postmenopausal estrogen and coronary atherosclerosis. Ann Intern Med 1988; 108: 358–369
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10(Suppl 1)1–78
   PubMedGoogle Scholar
• Williams J K, Anthony M S, Honore E K, Herrington D M, Morgan T M, Register T C, Clarkson T B. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995; 15: 827–836
   PubMed Web of Science ®Google Scholar
• Byington R P, Furberg C D, Herrington D M, Herd J A, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland C C, , Heart and Estrogen/Progestin Replacement Study Research Group, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002; 57: 193–197
   Google Scholar
• Drechsler D, Kornacewicz-Jach Z. Assessment of carotid arteries and pulse wave velocity in patients of three-vessel coronary artery disease. Kardiol Pol 2002; 57: 193–197
   Google Scholar
• Colditz G A, Willett W C, Stampfer M J, Rosner B, Speizer F E, Hennekens C H. Menopause and risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105–1110
   PubMed Web of Science ®Google Scholar
• Raggi P, Callister T Q, Cooil B, He Z X, Lippolis N J, Russo D J, Zelinger A, Mahmarian J J. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000; 101: 850–855
   PubMed Web of Science ®Google Scholar
• Curb J D, Prentice R L, Bray P F, Langer R D, Van Horn L, Barnabei V M, Bloch M J, Cyr M G, Gass M, Lepine L, Rodabough R J, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772–780
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller L H, Prentice R, Rodabough R J, Psaty B M, Stafford R S, Sidney S, Rosendaal F R, Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–1580
   PubMed Web of Science ®Google Scholar
• Kyrle P A, Minar E, Bialonczyk C. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558–2563
   PubMed Web of Science ®Google Scholar
• Simon T, Beau Yon De Jonage-Canonico M, Oger E, Wahl D, Conard J, Meyer G, Emmerich J, Barrellier M T, Guiraud A, Scarabin P Y, EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost 2006; 4: 71–76
   Google Scholar
• Daly E, Vessey M P, Hawkins M M, Carson J L, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–980
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Prentice R L, Manson J E, Wu L, Barad D, Barnabei V M, Ko M, LaCroix A Z, Margolis K L, Stefanick M L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006; 15: 35–44
   PubMed Web of Science ®Google Scholar
• Manson J E, Allison M A, Rossouw J E, Carr J J, Langer R D, Hsia J, Kuller L H, Cochrane B B, Hunt J R, Ludlam S E, Pettinger M B, , WHI and WHI-CACS Investigators, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591–2602
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E. Hormone replacement therapy. BMJ 1998; 317: 457–461
   PubMed Web of Science ®Google Scholar
• Scarabin P Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–432
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier M T, Wahl D, Emmerich J, , Estrogen and Thromboembolism Risk (ESTHER) Study Group, et al. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–845
   PubMed Web of Science ®Google Scholar
• Straczek C, Oger E, Yon de Jonage-Canonico M, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier M T, , Estrogen and Thromboembolism Risk (ESTHER) Study Group, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration. Circulation 2005; 112: 3495–3500
   PubMed Web of Science ®Google Scholar
• Koh K K, Jin D K, Yang S H, Lee S K, Hwang H Y, Kang M H, Kim W, Kim D S, Choi I S, Shin E K. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001; 103: 1961–1966
   PubMed Web of Science ®Google Scholar
• Corrao G, Zambon A, Nicotra F, Fornari C, La Vecchia C, Mezzanzanica M, Nappi R E, Merlino L, Cesana G. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes. Maturitas 2007; 57: 315–324
   Google Scholar
• Koh K K, Shin M S, Sakuma I, Ahn J Y, Jin D K, Kim H S, Kim D S, Han S H, Chung W J, Shin E K. Effects of conventional or lower closes of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24: 1516–1521
   PubMed Web of Science ®Google Scholar